August 8, 2017 - HCAP Partners has exited its investment in Parallel 6, Inc., a mobile clinical SaaS platform designed to recruit, enroll, engage and manage patients in clinical trials. P6 was recently sold to PRA Health Sciences, Inc. (NASDAQ: PRAH).
April 14, 2016: HCAP Partners portfolio company, Parallel 6, announced that they were named one of the 2016 Top 10 eClinical Trial Management Solution Providers by Pharma Tech Outlook magazine.
January 7, 2016: HCAP Partners' Portfolio Company, Parallel 6, Acquires nPruv, Inc. A Clinical Trial Patient Matching and Predictive Modeling Technology Company.
April 13, 2015: Huntington Capital Fund III, LP announces the completion of a $3.0 million convertible senior mezzanine loan commitment in Parallel 6, Inc., a mobile engagement management solution provider. The new financing will be used to recapitalize certain debt and to support the Company’s growth into new markets.